Published in Mutat Res on February 21, 2010
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 4.30
Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys (2006) 2.92
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat (2008) 2.59
[18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol (2006) 2.22
An anatomically validated brachial plexus contouring method for intensity modulated radiation therapy planning. Int J Radiat Oncol Biol Phys (2013) 2.13
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09
Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J (2004) 2.01
Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol (2008) 2.00
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91
Accuracy of patient dose calculation for lung IMRT: A comparison of Monte Carlo, convolution/superposition, and pencil beam computations. Med Phys (2006) 1.66
Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65
The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol (2003) 1.64
Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys (2004) 1.50
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: the need to investigate the accuracy of dose computation. Radiother Oncol (2005) 1.44
Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr (2007) 1.38
Prenylated chalcone xanthohumol associates with histones in breast cancer cells--a novel target identified by a monoclonal antibody. Mol Nutr Food Res (2012) 1.38
Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys (2010) 1.33
EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32
An ex(o)citing machinery for invasive tumor growth. Cancer Res (2010) 1.31
Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res (2010) 1.30
A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas (2006) 1.29
Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) -- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res (2005) 1.27
Autophagy in disease: a double-edged sword with therapeutic potential. Clin Sci (Lond) (2009) 1.26
Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene (2004) 1.26
Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding. J Cell Sci (2004) 1.24
Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys (2009) 1.22
Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys (2008) 1.20
Soluble cadherins as cancer biomarkers. Clin Exp Metastasis (2007) 1.20
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut (2012) 1.19
Dosimetric characterization of GafChromic EBT film and its implication on film dosimetry quality assurance. Phys Med Biol (2007) 1.18
Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol (2007) 1.18
Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol (2010) 1.17
Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol (2006) 1.16
Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys (2004) 1.16
Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer (2008) 1.15
Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer (2014) 1.13
Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer (2005) 1.13
Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.13
Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett (2007) 1.11
Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
Prediction of late normal tissue complications in RT treated gynaecological cancer patients: potential of the gamma-H2AX foci assay and association with chromosomal radiosensitivity. Oncol Rep (2010) 1.10
Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol Chem (2002) 1.09
Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.08
Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol (2010) 1.08
Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys (2008) 1.07
IMRT treatment planning:- a comparative inter-system and inter-centre planning exercise of the ESTRO QUASIMODO group. Radiother Oncol (2005) 1.06
P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res (2004) 1.05
Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer (2005) 1.04
The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol (2005) 1.03
Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol (2011) 1.02
Conversion of CT numbers into tissue parameters for Monte Carlo dose calculations: a multi-centre study. Phys Med Biol (2007) 1.02
The secretory small GTPase Rab27B as a marker for breast cancer progression. Oncotarget (2010) 1.01
Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer (2013) 1.01
The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol (2011) 1.00
Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol (2013) 1.00
P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res (2005) 1.00
TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys (2006) 0.99
Predicting risk of radiation-induced lung injury. J Thorac Oncol (2007) 0.99
Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol (2008) 0.99
Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br J Nutr (2007) 0.99
Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res (2005) 0.98
Roles for neuregulins in human cancer. Clin Exp Metastasis (2004) 0.98
Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J Radiat Oncol Biol Phys (2003) 0.98
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol (2009) 0.96
DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res (2012) 0.96
TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J (2008) 0.96
Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT? Radiat Oncol (2013) 0.95
Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol (2013) 0.95
No association between TGF-β1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients. Radiother Oncol (2012) 0.95
Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett (2008) 0.95
Disposition of hop prenylflavonoids in human breast tissue. Mol Nutr Food Res (2010) 0.94
Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys (2012) 0.94
Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics (2013) 0.94
Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol (2010) 0.93
The tandem PDZ domains of syntenin promote cell invasion. Exp Cell Res (2007) 0.93
Intensity modulating and other radiation therapy devices for dose painting. J Clin Oncol (2007) 0.92
Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli. Microb Biotechnol (2011) 0.92
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol (2010) 0.92
Chronic lymphocytic leukaemia. Anticancer Res (2009) 0.92
IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys (2011) 0.92
The HMI™ module: a new tool to study the Host-Microbiota Interaction in the human gastrointestinal tract in vitro. BMC Microbiol (2014) 0.92
Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Rev Proteomics (2012) 0.92
Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS One (2013) 0.92
Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions. Radiother Oncol (2013) 0.91
Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat Res (2008) 0.91